Worth Watching Stock: Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) reported earnings for the three months ended Mar2016 on April 21, 2016. The company earned $4.79 per share on revenue of $2.73B. Analysts had been modeling earning per share of $4.47 with $2.75B in revenue.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company’s products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer’s disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis.

Biogen Inc. earnings per share showed an increasing trend of 24% for the current fiscal year. The company’s expected EPS growth rate for next fiscal year is 2008%.Analysts project EPS growth over the next 5 years at 9.45%. It has EPS annual growth over the past 5 fiscal years of 31.3% when sales grew 17.9. It reported 6.7% sales growth, and 26.8% EPS growth in the last quarter.

The stock is trading at $289.73, up 19.69% from 52-week low of $242.07. The stock trades down -31.18% from its peak of $420.99 and 19.25% above the consensus price target of $345.5. Its volume clocked up at 2.15 million shares which is higher than the average volume of 1.63 million shares. Its market capitalization currently stands at $61.95B.